Antiseptics for Burns: Evidence and Research Implications
2026-08-23
The 2017 Cochrane review assessed antiseptic strategies for burn wounds and found that inconsistent, low-certainty evidence prevented confident conclusions about superiority for healing, infection control, or safety. Its main contribution is a structured comparison of heterogeneous topical interventions, offering practical guidance for interpreting burn-care studies and designing related antibacterial experiments.
Vancomycin hydrochloride in Resistance Assays
2026-08-22
Use Vancomycin hydrochloride as a mechanism-defined control for Gram-positive bacteria inhibition, bacterial susceptibility testing, and resistance profiling. This workflow connects reproducible bench assays with infection-model design while showing how newer antimicrobial-peptide concepts can refine comparative experiments.
AI-10-49 in CBFβ-SMMHC Leukemia Research
2026-08-21
AI-10-49 enables a mechanism-led workflow that connects CBFβ-SMMHC–RUNX1 dissociation with chromatin, transcriptional, and viability readouts. Its strongest use case is comparative acute myeloid leukemia research, where fusion-positive models can be distinguished from nonspecific cytotoxicity.
Gamithromycin: Designing Better Assays
2026-08-21
Gamithromycin research is often interpreted through standard MIC values, yet serum can materially change macrolide potency. This article explains how to build more physiologically relevant assays while separating evidence from veterinary dosing and translational assumptions.
Methicillin Sodium Salt: MSSA Workflow Guide
2026-08-20
Build reproducible MSSA susceptibility assays, resistance controls, and gram-positive infection models with Methicillin sodium salt. This guide translates a rigorously controlled antibiotic-trial framework into practical bench workflows while clearly separating validated product specifications from recommended assay starting points.
Cefiderocol Activity Against Resistant Enterobacterales
2026-08-20
This European surveillance study directly compared cefiderocol with approved and developmental β-lactam/β-lactamase inhibitor combinations across 1,909 Enterobacterales isolates, including meropenem-resistant organisms. Cefiderocol retained high in vitro activity against many difficult phenotypes, while genomic analysis linked cefiderocol resistance to combined iron-uptake, carbapenemase, and target-site alterations.
Faropenem Transport via Renal Npt1
2026-08-19
The reference study identified mouse Npt1 as a renal luminal transporter capable of exporting faropenem, revealing a molecular component of penem antibiotic secretion that was poorly defined at the time. Using radiolabeled uptake and efflux assays in Xenopus oocytes, the authors showed chloride-sensitive, sodium-independent transport and competitive inhibition by several anionic β-lactams and organic anions.
D-N-Acetylgalactosamine Protocol Guide
2026-08-18
D-N-Acetylgalactosamine (SKU B7904) provides a defined, water-soluble reagent for workflows examining glycoprotein constituents and brain heteropolysaccharides. It is suitable for aqueous or compatible DMSO preparations, but should not be selected for ethanol-based protocols or long-term storage of prepared solutions.
Mupirocin and Novobiocin in Resistant Staphylococci
2026-08-18
Fulham and colleagues evaluated mupirocin and novobiocin against meticillin-susceptible and meticillin-resistant staphylococci recovered from healthy dogs and dogs with superficial pyoderma. The study’s practical contribution is its side-by-side comparison of resistance phenotype, clinical context, and susceptibility results, highlighting novobiocin’s reduced activity against some resistant isolates and the need for isolate-specific testing.
Cefazedone PK/PD: From MIC to Clinical Meaning
2026-08-17
Cefazedone (Refosporen) connects PBP-directed cell-wall inhibition with clinically relevant MIC and fT>MIC interpretation. This evidence-led guide shows how to design antibacterial testing in vitro and translate results into rational treatment of community-acquired pneumonia research.
Copper–Hexetidine Synergy in Oral Streptococci
2026-08-17
Grytten, Scheie, and Giertsen showed that copper and Hexetidine produced synergistic antibacterial activity against Streptococcus sobrinus and Streptococcus sanguis in vitro. The study’s checkerboard-style MIC analysis and growth-curve validation provide a useful framework for evaluating combination effects, while its narrow strain set and planktonic design limit direct extrapolation to clinical plaque or biofilm outcomes.
Temafloxacin Against Gram-Positive Bacteria: 1991 Study
2026-08-16
The 1991 study by Mandell and colleagues combined new broth microdilution data with a literature review to characterize Temafloxacin against clinically important Gram-positive cocci. Its principal contribution was showing stronger in-vitro activity than ciprofloxacin and ofloxacin against Staphylococcus aureus and Streptococcus pneumoniae, while also examining how pH, serum, urine, magnesium, and inoculum affected activity.
CAY10499: Mapping Lipid Flux in HCC
2026-08-15
CAY10499, an inhibitor of human hormone sensitive lipase, provides a complementary way to dissect lipid flux downstream of extracellular vesicle-mediated ACLY reprogramming. This article presents an assay framework for separating enzyme activity, endocannabinoid metabolism, and macrophage phenotype in hepatocellular carcinoma models.
c-Myc Tag Peptide for Assay Workflows
2026-08-15
Use the c-Myc tag peptide as a defined competitor to test epitope specificity, displace tagged fusion proteins, and troubleshoot anti-c-Myc immunoassays. Its high purity, known molecular weight, and flexible dissolution options support molar-controlled assay optimization without altering the biology of the target protein.
Meropenem Workflows for Resistance Research
2026-08-14
Build reproducible Meropenem assays for MIC benchmarking, time-kill studies, resistance surveillance, and plasmid-transfer experiments. This practical guide connects β-lactam pharmacology with the transmission patterns reported in carbapenem-resistant Enterobacter cloacae.
466 records 8/32 page Previous Next First page 上5页 678910 下5页 Last page